DC Migration Study for Newly-Diagnosed GBM

Summary

DC Migration Study for Newly-Diagnosed GBM is a clinical trial^[1].

Key Facts

• DC Migration Study for Newly-Diagnosed GBM is in the country of United States^[2].
• DC Migration Study for Newly-Diagnosed GBM's instance of is recorded as clinical trial^[3].
• DC Migration Study for Newly-Diagnosed GBM's start time is recorded as +2015-10-12T00:00:00Z^[4].
• DC Migration Study for Newly-Diagnosed GBM's end time is recorded as +2020-06-30T00:00:00Z^[5].
• DC Migration Study for Newly-Diagnosed GBM's main subject is recorded as astrocytoma^[6].
• DC Migration Study for Newly-Diagnosed GBM's number of participants is recorded as {'unit': '1', 'amount': '+100'}^[7].
• DC Migration Study for Newly-Diagnosed GBM's title is recorded as Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma^[8].
• DC Migration Study for Newly-Diagnosed GBM's short name is recorded as ELEVATE^[9].
• DC Migration Study for Newly-Diagnosed GBM's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• DC Migration Study for Newly-Diagnosed GBM's ClinicalTrials.gov ID is recorded as NCT02366728^[11].
• DC Migration Study for Newly-Diagnosed GBM's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+80'}^[12].
• DC Migration Study for Newly-Diagnosed GBM's research intervention is recorded as basiliximab^[13].
• DC Migration Study for Newly-Diagnosed GBM's research intervention is recorded as temozolomide^[14].
• DC Migration Study for Newly-Diagnosed GBM's clinical trial phase is recorded as phase II clinical trial^[15].
• DC Migration Study for Newly-Diagnosed GBM's research site is recorded as Duke University Medical Center^[16].
• DC Migration Study for Newly-Diagnosed GBM's study type is recorded as interventional study^[17].